抗体-药物结合体在尿路癌中:目前的状况和未来的情况
Samuel Ruder1, Juana Martinez2, Jessica Palmer1
1Department of Medicine, Division of Hematology and Oncology, New York Presbyterian Weill Cornell Medical Center.
Current opinion in urology
|January 23, 2025
概括
针对nectin-4,Trop-2和HER-2的抗体-药物结合体 (ADC) 正在推进尿路细胞癌治疗. 恩福图马布维多丁和萨基图祖马布戈维特可以显示出有希望的结果,HER-2ADC正在调查中.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗体 - 药物结合体 (ADC) 在治疗各种癌症,包括尿路细胞癌中变得越来越重要.
- 针对特定抗原的几种ADC正在为尿路细胞癌进行临床研究.
研究的目的:
- 审查最近对针对尿素-4,Trop-2,HER-2和其他抗原的ADCs的临床研究.
- 总结这些ADC的疗效,毒性,耐药性机制和临床前数据.
主要方法:
- 临床试验和临床前研究的文献综述关于尿癌中ADCs.
- 对单独使用ADC和与免疫治疗结合使用ADC的疗效和毒性数据的分析.
主要成果:
- 恩福图马布维多丁和萨基图祖马布戈维特康在未经选择的尿癌患者中是有效的.
- HER-2 ADCs有希望,但仅限于HER-2表达/放大率高的患者.
- 组合疗法,特别是与免疫检查点抑制剂的组合疗法,正在积极研究中.
结论:
- 恩福图马布维多丁加上布罗利祖马布被支持作为转移性/不可切除的局部晚期泌尿腺癌的第一线治疗.
- 萨西图祖马布 (Sacituzumab) govitecan可以作为后续的选择.
- 针对HER-2的ADC治疗是有希望的,需要进一步研究.
更多相关视频
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.2K
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.2K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:31Hybridoma Technology
14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K